BDC's Dion Madsen, CTI's Shermaine Tilley depart Zymeworks board
Shermaine Tilley, a managing partner at CTI Life Sciences Fund, and Dion Madsen, a senior managing partner at BDC Capital, have left the board of directors of Zymeworks Inc (NYSE, TSX: ZYME). The resignations, which also included Eli Lilly & Co's Kerry Blanchard, follow Zymeworks' initial public offering in Canada and the United States, which wrapped up earlier this month. Vancouver-based Zymeworks, a biotherapeutics provider, went public after raising nearly US$150 million from a mix of venture capital and strategic investors.
9 May 2017•2 mins read
